Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Alectinib - Usual · 1 trial · 1 indication
* Recruit 300 double blind random group separated NSCLC patients currently using the Chemotherapy NDC...01 on ALECENSA - alectinib 600 mg orally twice daily, after biopsy diagnosis, to be the usual approach group. * Recruit 300 double blind random group separated NSCLC patients currently using the Chemotherapy NDC...86 on ALECENSA - alectinib 600 mg orally twice daily, after biopsy diagnosis, to be the study approach group. * Measure above every NSCLC patient-specific Alectinib drug target (ALK) SNP genotype in his or her WBC cell whole genome DNA with Oxford precisely sequencing. * Report every NSCLC patient-specific ALK SNP genotype in whole genome DNA sequence. * Measure above every NSCLC patient-specific Alectinib drug target (CYP4503A4) SNP genotype in his or her WBC cell whole genome DNA with Oxford precisely sequencing. * Report every NSCLC patient-specific CYP4503A4 SNP genotype in whole genome DNA sequence.
| Arm | Type | Description |
|---|---|---|
| Alectinib - Usual | EXPERIMENTAL | * Usual ALECENSA - Alectinib * Chemotherapy (NDC...01) * Usual ALECENSA - alectinib hydrochloride capsule 600 mg orally twice daily * Usual Approach Group (NDC...01) * ALECENSA - alectinib hydrochloride capsule -- 600 mg orally twice daily |
| Alectinib - Study | EXPERIMENTAL | * Study ALECENSA - Alectinib * Chemotherapy (NDC...86) * Study ALECENSA - alectinib hydrochloride capsule 600 mg orally twice daily * Study Approach Group (NDC...86) * ALECENSA - alectinib hydrochloride capsule -- 600 mg orally twice daily |
| Name | Type | Description |
|---|---|---|
| Alectinib - Usual | DRUG | Usual Alectinib Chemotherapy (NDC...01) \- ALECENSA - alectinib hydrochloride capsule -- 600 mg orally twice daily |
| Alectinib - Study | DRUG | Study Alectinib Chemotherapy (NDC...86) \- ALECENSA - alectinib hydrochloride capsule -- 600 mg orally twice daily |
* Select 600 Non-Small Cell Lung Cancer Patients who are suitable for blood-drawing. * Dosage Duration at least 90 days * The usual approach group - Recruit 300 double blind random group separated NSCLC patients currently used the Chemotherapy NDC...01 on ALECENSA - alectinib hydrochloride capsule 6...
Top 20 of 84 competitors
Alectinib - Usual is an investigational small molecule being studied for the treatment of Non-small Cell Lung Cancer. It is currently in Phase 2 clinical development. The drug is being evaluated in a randomized, double-blind, controlled trial that uses a biomarker to select patients.
Alectinib - Usual targets ALK, EML4, and RET, and it is an inhibitor of these molecular targets. By inhibiting these targets, the drug is designed to interfere with cancer cell growth and survival in Non-small Cell Lung Cancer.
Alectinib - Usual is being developed by Design Therapeutics, Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol DSGN. The company is conducting clinical research on this drug for Non-small Cell Lung Cancer.
Alectinib - Usual is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials to assess its safety and efficacy for Non-small Cell Lung Cancer.
Alectinib - Usual is being studied in one active clinical trial with the identifier NCT05987956. This Phase 2 trial, titled 'Pharmacogenomics IND EXEMPT SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms,' is enrolling 600 participants with Non-small Cell Lung Cancer in the United States.
Alectinib - Usual is a specific formulation or version of alectinib, a drug that targets ALK, EML4, and RET. It is being developed by Design Therapeutics, Inc. under the name Alectinib - Usual for Non-small Cell Lung Cancer.